Janus kinase (JAK) inhibitors led to improvement of uveitis in approximately half of pediatric patients previously treated with disease-modifying antirheumatic drugs (DMARDs) in a case series.
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...
Medpage Today on MSN
JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis
Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...
They’ve been approved for the US market since 2012, but Janus kinase (JAK) inhibitors are still the new kid on the block in terms of rheumatoid arthritis treatment. As such, the real-world evidence on ...
JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. JAK inhibitors inhibit a broader cytokine profile than ...
SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...
Janus kinase (JAK) inhibitors are not only efficacious in terms of skin disease improvement, but also in terms of itch management, explained Mona Shahriari, MD, assistant clinical professor of ...
Over the past decade, patients with moderate to severe rheumatoid arthritis who have not had success with established treatments have been able to turn to a new class of drugs called Janus kinase (JAK ...
Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...
Please provide your email address to receive an email when new articles are posted on . Acne was an adverse event for 6.2% of patients treated with Janus kinase (JAK) inhibitors vs. 1.3% of controls.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback